In this article
Introduction
Swiss pharmaceutical giant Roche announced the PD-L1 tumor immunotherapy Tecentriq (atezolizumab) combined with Avastin (bevacizumab, bevacizumab) in the treatment of unresectable or advanced hepatocellular carcinoma (HCC) at ESMO 2018 in Munich, Germany ) The latest data from the Phase Ib clinical study (NCT02715531).
Trial Results
The efficacy evaluation group included all patients who received combination therapy and were followed for at least 16 weeks, with a median survival follow-up time of 7 months. In terms of complete response rate (CR), the CR assessed by INV according to RECIST v1.1 was 1 case (1%), the CR assessed by IRF according to RECIST v1.1 was 4 cases (5%), and the CR assessed by IRF according to HCC mRECIST was 8 cases (11%). The disease control rate (DCR, ie experienced remission or stable condition) was consistent in all forms of evaluation, INV’s DCR was 77% according to RECIST v1.1 (n = 56/73), IRF was based on RECIST v1.1 And the DCR according to HCC mRECIST is 75% (55/73). The median duration of remission (DOR) and overall survival (OS) have not been reached.
In the safety-evaluable group (n = 103), 27% of patients (n = 28/103) experienced grade 3-4 treatment-related adverse events and 2% (n = 2/103) experienced treatment-related grade 5 adverse events event. In addition to the safety profile of existing single drugs, no new safety signals related to combination therapy have been found.
In July this year, based on the overall data of the ongoing phase Ib study, the US FDA has granted Tecentriq + Avastin combination therapy as a first-line treatment for advanced or metastatic hepatocellular carcinoma (BTD). This is also the 23rd BTD awarded in Roche’s product portfolio to date and the 3rd BTD awarded by Tecentriq to date.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
About Susan Hau
Susan Hau is a distinguished researcher in the field of cancer cell therapy, with a particular focus on T cell-based approaches and cancer vaccines. Her work spans several innovative treatment modalities, including CAR T-cell therapy, TIL (Tumor-Infiltrating Lymphocyte) therapy, and NK (Natural Killer) cell therapy. Hau's expertise lies in cancer cell biolo…
✓ Reviewed for medical accuracy by the CancerFax review panel.
Related Topics
Medical Disclaimer
This article is for educational purposes only and should not replace medical advice, diagnosis, or treatment from a qualified oncology specialist. Every patient's case is different. Treatment decisions should always be made after a review of complete medical records by the treating medical team.
Treatment availability, eligibility, timelines, and access can change. Any clinical trial participation depends on detailed review and approval by the trial hospital or investigator.